KLK3 and neoplasm: It is, however, not without limitations, especially in the metastatic CRPC (mCRPC) setting where early elevations (flare phenomena) as PSA is released from apoptotic cells make it difficult to use PSA kinetics to monitor the tumor burden with sufficient precision.